Quick Answer
Lexaria Bioscience Corp. reported Revenue (ASC 606) of $384.5 thousand for fiscal year 2020.
Lexaria Bioscience Corp. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2020 | $384.5K | +72.7% |
| 2019 | $222.6K | -48.6% |
| 2018 | $433.3K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| May 31, 2021 | $204.1K | +460.2% | +6.3% |
| February 28, 2021 | $192.0K | +411.3% | -35.1% |
| November 30, 2020 | $295.7K | +2761.6% | +711.7% |
| May 31, 2020 | $36.4K | -39.2% | -3.0% |
| February 29, 2020 | $37.5K | +144.6% | +263.4% |
| November 30, 2019 | $10.3K | -53.5% | -82.8% |
| May 31, 2019 | $59.9K | -57.3% | +290.5% |
| February 28, 2019 | $15.3K | -91.1% | -30.9% |
- Lexaria Bioscience Corp. showed an increase of +72.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2020 period, Lexaria Bioscience Corp.’s revenue (asc 606) has declined by 11.2% (from $433.3 thousand to $384.5 thousand).
- The most recent figure is from Lexaria Bioscience Corp.’s fiscal year 2020 report (Form 10-K), filed with the SEC on October 15, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: